Skip to main content

Table 1 Baseline characteristics and mortality rate for patients with non-ventilator-associated ICU-acquired pneumonia admitted to an ICU for severe acute exacerbation of chronic obstructive pulmonary disease

From: Correction: Non-ventilator-associated ICU-acquired pneumonia (NV-ICU-AP) in patients with acute exacerbation of COPD: From the French OUTCOMEREA cohort

 

No NV-ICU-AP (n = 802)

NV-ICU-AP (n = 42)

p value

Median [Q1; Q3] or n (percentage)

Median [Q1; Q3] or n (percentage)

Baseline characteristics

Age (years)

70.7 [62.0; 78.1]

72.3 [67.6; 76.9]

0.33

Male sex, n (%)

499 (62.2)

31 (73.8)

0.13

BMI (kg/m2)

24.9 [20.8; 30.3]

23.9 [21.2; 30.1]

0.74

SAPS II score

34.0 [26.0; 42.0]

38.0 [30.0; 45.0]

0.05

Maximum SOFA Day 1- Day 2

4.0 [3.0; 6.0]

5.0 [3.0; 6.0]

0.06

Hospitalisation before ICU admission (yes), n (%)

264 (32.9)

20 (47.6)

0.05

Immunodeficiency (yes), n (%)

74 (9.2)

6 (14.3)

0.28

No decrease in consciousness Day 1- Day 2 (Glasgow Coma Scale = 15)

490 (61.1)

14 (33.1)

< 0.01

MDR bacterial colonization, (yes), n (%)

47 (5.9)

3 (7.1)

0.73

COPD severity

Very Severe COPD, n (%)

173 (21.6)

1 (2.4)

< 0.01

Trigger of the acute exacerbation of COPD

Respiratory infection, n (%)

524 (65.3)

29 (69.0)

0.74

Non-infectious respiratory causes, n (%)

165 (20.6)

8 (19.0)

 

Cardiac and thromboembolic events, n (%)

63 (7.9)

4 (9.5)

 

Others, n (%)

50 (6.2)

1 (2.4)

 

Therapeutic limitation

Limitation of therapeutic effort at admission to ICU, (yes) n (%)

63 (7.9)

3 (7.1)

0.87

Corticosteroid therapy

Use of corticosteroids therapy at admission, (yes) n (%)

302 (37.7)

12 (28.6)

0.24

Antibiotic therapy

Use of antibiotic therapy at admission, (yes) n (%)

561 (70.0)

25 (59.5)

0.15

Gastroprotective agents

Use of gastroprotective agents at admission, (yes) n (%)

411 (51.2)

22 (52.4)

0.89

Enteral nutrition

Use of enteral nutrition at admission, (yes) n (%)

99 (12.3)

10 (23.8)

0.03

Lengths of stay

ICU Length of stay (days)

6.0 [5.0; 10.0]

24.5 [14.0; 37.0]

< 0.01

Hospital Length of stay (days)

18.0 [12.0; 30.0]

37.0 [22.0; 59.0]

< 0.01

Mortality

ICU Mortality rate, n (%)

73 (9.1)

16 (38.1)

< 0.01

Hospital Mortality rate, n (%)

123 (15.3)

18 (42.9)

< 0.01

Mortality at Day 28, n (%)

96 (12.0)

10 (23.8)

0.02

Non-ventilator-associated ICU-acquired pneumonia

Day of first diagnosis of NV-ICU-AP (days in ICU)

–

6.0 [4.0; 11.0]

 

Day of first diagnosis of NV-ICU-AP (days in hospital)

–

7.5 [5.0; 16.0]

 

NV-ICU-AP requiring intubation, (yes) n (%)

–

32 (76.2)

 
  1. Very Severe COPD = Oxygen therapy at home or NIV at home or Airflow limitation Stage 4. The use of corticosteroids therapy at admission was defined as a daily dose ≥ 0.5 mg/kg of prednisone or equivalent prescribed during the first 24 h after admission in ICU for the current AECOPD. Immunodeficiency was defined by the presence of aplasia, corticosteroid therapy for more than one month or at a dose > 2mg/kg of prednisone equivalent, chemotherapy, human immunodeficiency virus (HIV) at the acquired immunodeficiency syndrome (AIDS) stage or organ transplantation. Bacterial colonisation was defined by the presence of MDROs on screening samples taken on admission in ICU. These MDROs correspond to methicillin-resistant Staphylococcus aureus, extended-spectrum β-lactamase–producing Enterobacteriaceae, AmpC-producing Enterobacteriaceae, and Pseudomonas aeruginosa resistant to ticarcillin and/or imipenem and/or ceftazidime in the bacteriological samples
  2. ICU, Intensive Care Unit; BMI, Body Mass Index, SAPS II, Simplified Acute Physiology Score II, SOFA Score, Sequential Organ Failure Assessment Score; COPD, Chronic Obstructive Pulmonary Disease, NV-ICU-AP, Non-ventilator-associated Intensive Care Unit Acquired Pneumonia
Back to article page

Critical Care

ISSN: 1364-8535